Adaptive Biotechnologies Corp (ADPT)
$6.71 $0.54 (8.31%) 4:37 PM 12/10/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$925.32M -
Day's Range
$6.28 - $7.07 -
Volume
1,532,267 -
52 Week Low / High
$2.28 - $6.70 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 3
- Strong Buy
- 3
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong Sell
- $12.14
- Target Price
Company News
-
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 — Oct 9th, 2024
Adaptive Biotechnologies SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today a...
-
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 — Oct 9th, 2024
Adaptive Biotechnologies SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today a...
-
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 — Oct 9th, 2024
Adaptive Biotechnologies SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today a...
-
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 — Oct 9th, 2024
Adaptive Biotechnologies SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today a...
-
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 — Oct 9th, 2024
Adaptive Biotechnologies SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today a...
-
Adaptive Announces IVDR Certification for clonoSEQ® in European Union — Aug 29th, 2024
Adaptive Biotechnologies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims ...
-
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 — Oct 9th, 2024
Adaptive Biotechnologies SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today a...
-
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 — Oct 9th, 2024
Adaptive Biotechnologies SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today a...
-
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 — Oct 9th, 2024
Adaptive Biotechnologies SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today a...
Portfolio
Comprised of 1 portfolios